Answer
Worsening respiratory symptoms such as dyspnoea (breathlessness), cough and fever during lorlatinib treatment can suggest interstitial lung disease or pneumonitis and require prompt evaluation.
Sources for this answer
- Lorviqua 25 mg film coated tablets,Pfizer Limited · emc · SmPC §4.4 Special warnings and precautions for use · Version 14Document updated
Sources checked